Ipilimumab/NivolumabAutoimmune-hepatitis: case report

被引：0

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2038卷 / 1期

关键词：

D O I：

10.1007/s40278-024-72276-1

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：167 / 167

相关论文

共 50 条

[31] Ipilimumab/nivolumabAutoimmune thyroiditis leading to thyrotoxicosis and delirium: case report [J].

Reactions Weekly, 2025, 2050 (1) :282-282

[32] Ipilimumab/nivolumabAutoimmune encephalitis: 2 case reports [J].

Reactions Weekly, 2016, 1620 (1) :101-101

[33] Ipilimumab/nivolumabAutoimmune encephalitis: 2 case reports [J].

Reactions Weekly, 2019, 1782 (1) :186-186

[34] Ipilimumab/nivolumabEnteritis and hepatitis: case report [J].

Reactions Weekly, 2018, 1696 (1) :214-214

[35] Ipilimumab/NivolumabImmune hepatitis: case report [J].

Reactions Weekly, 2024, 2037 (1) :219-219

[36] Ipilimumab/nivolumabAutoimmune hypophysitis [J].

Reactions Weekly, 2023, 1985 (1) :271-271

[37] NivolumabAutoimmune gastritis: case report [J].

Reactions Weekly, 2022, 1900 (1) :254-254

[38] NivolumabAutoimmune encephalitis: case report [J].

Reactions Weekly, 2018, 1684 (1) :194-194

[39] NivolumabAutoimmune diabetes: case report [J].

Reactions Weekly, 2017, 1651 (1) :239-239

[40] NivolumabAutoimmune thyroiditis: case report [J].

Reactions Weekly, 2020, 1795 (1) :206-206

← 1 2 3 4 5 →